DigiCon

What is the ratio of non-metastatic to metastatic stage prostate cancer patients in your clinical practice? *

10 % non-metastatic: 90% metastatic

20 % non-metastatic: 80% metastatic

30 % non-metastatic: 70% metastatic

40 % non-metastatic: 60% metastatic

50 % non-metastatic: 50% metastatic

In your clinical practice amongst the below mentioned profile of advanced prostate cancer, which profile of patients are considered as high-risk patients? *

Patients with cardiovascular co-morbidities

Patients with skeletal pain

Patients with bone pain

Patients with severe urinary obstruction

Paraplegic/Quadriplegic patients

Any Other

In your practice what percentage of advanced prostate cancer patients in CSPC stage belong to high-risk category *

10-20%

21%-30%

31%-40%

41%-50%

>50%

Among the high-risk patient categories (including those with cardiovascular comorbidities, skeletal pain, bone pain, severe obstruction, and paraplegia/quadriplegia), which specific group do you encounter most frequently in your clinical practice? *

In your current clinical practice, what is the ratio of surgical castration to medical castration for managing prostate cancer patients? *

50 % surgical castration: 50% medical castration

60 % surgical castration: 40% medical castration

70 % surgical castration: 30% medical castration

80 % surgical castration: 20% medical castration

If Surgical castration is preferred in specific patients, could you specify reasons

In medical castration, which is your preferred option? *

LHRH Agonist

LHRH Antagonist (Injectable)

LHRH Antagonist (Oral)

Among the GnRH agonists, which specific molecule do you prefer for your patients, and what are your reasons for this choice? *

Leuprolide acetate

Triptorelin

Goserelin

Reasons for preferring the molecule

Do you prefer using 6 monthly Leuprolide acetate depot (45mg) in your clinical practice? *

Yes

No

If yes, could you specify in which category of patients would you prefer 6 monthly depot?

If no, could you specify the reason for not preferring LHRH agonist (6 MO, 45MG) depot in your practice?

In which profile of patients do you prefer using GnRH antagonist, Degarelix? *

In which profile of patients do you prefer using GnRH antagonist, Relugolix? *

Do you prefer shifting the patient from LHRH antagonist to agonist after induction dose with antagonist? *

Yes

No

If yes, could you specify reasons for following the protocol

In your clinical practice in what percentage of advanced prostate cancer patients would you be initiating ADT + Abiraterone/Enzalutamide upfront in CSPC stage *

<5%

5-10%

11-15%

16-20%

>20%

When the patient progresses from CSPC stage to CRPC stage what are the parameters considered to confirm disease progression (select all that applies) *

PSA Progression

Radiographic progression

Clinical progression (Quality of life)

All the above

Do you prefer continuing ADT with Abiraterone/Enzalutamide in mCRPC patients? *

Yes

No

What is the preferred line of treatment for CSPC patients when they progress on ADT to mCRPC stage? *

Refer the patient to Medical Oncologist

Initiate Abiraterone acetate + Prednisone

Initiate Enzalutamide

In case you are referring the patients to medical oncologist in CRPC stage please share reason for the same when currently both Abiraterone acetate and Enzalutamide are available as treatment options as per guidelines *

Between Abiraterone and Enzalutamide which is your preferred first line of treatment in MCRPC patients *

Abiraterone followed by Enzalutamide

Enzalutamide followed by Abiraterone

Any specific reason for following the sequence mentioned in Q.21? *

What percentage of advanced prostate cancer patients in your practice would need Bisphosphonates/monoclonal antibodies as a supportive therapy? *

<5%

5-10%

11-15%

16-20%

>20%

In what percentage of advanced prostate cancer patients do you initiate zoledronic acid? *

<5%

5-10%

11-15%

16-20%

>20%

Have you utilized Denosumab in your clinical practice? *

Yes

No

If yes, could you highlight any specific benefits Denosumab offers compared to Zoledronic acid?

If you have used denosumab in your clinical practice what is the preferred dosage between 60mg & 120mg

Any specific patient profile where Denosumab shows better efficacy/tolerability vs Zoledronic acid?

{{ $ActivityTypeName }}

A Survey of Urologists to understand the current perception and practice in the Management of Prostate Cancer Patients

Doctor's details

Current Practice Patterns